Author:
Kesselheim Aaron S.,Myers Jessica A.,Solomon Daniel H.,Winkelmayer Wolfgang C.,Levin Raisa,Avorn Jerry
Publisher
Public Library of Science (PLoS)
Reference37 articles.
1. How drugs for rare diseases became lifeline for companies.;G Anand,2005
2. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?;O Wellman-Labadie;Health Policy,2010
3. Does orphan drug legislation really answer the needs of patients?;ME Haffner;Lancet,2008
4. The Orphan Drug Act: an engine of innovation? At what cost?;DD Rohde;Food Drug Law J,2000
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending;Value in Health;2024-04
2. Challenges and Future Opportunities in Rare Genetic Disorders: A Comprehensive Review;Rare Genetic Disorders;2024
3. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy;The European Journal of Health Economics;2023-11-14
4. Investigation of the diagnostic importance and accuracy of CT in the chest compared to the RT-PCR test for suspected COVID-19 patients in Jordan;F1000Research;2023-11-13
5. Pharmaceutical policy and innovation for rare diseases: A narrative review;F1000Research;2023-11-13